Ident. | Authors (with country if any) | Title |
---|
000097 (2013) |
Vjera Holthoff [Allemagne] ; Steven Ferris [États-Unis] ; Serge Gauthier [Canada] ; Ralf Ihl [Allemagne] ; Philippe Robert [France] ; Bengt Winblad [Suède] ; Kati Sternberg [Allemagne] ; Frank Tennigkeit [Suisse] | Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open‐label, single‐arm, multicenter clinical study |
000122 (2013) |
Andrea Gold [Canada] ; Zorbey T. Turkalp [Canada] ; David G. Munoz [Canada] | Enteric alpha‐synuclein expression is increased in Parkinson's disease but not Alzheimer's disease |
000149 (2013) |
D. William Molloy [Irlande (pays)] ; T. I. Standish [Canada] ; Q. Zhou [Canada] ; G. Guyatt [Canada] | A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial |
000271 (2012) |
Mun-Gwan Hong [Suède] ; Chandra A. Reynolds [États-Unis] ; Adina L. Feldman [Suède] ; Mikael Kallin [Suède] ; Jean-Charles Lambert [France] ; Philippe Amouyel [France] ; Erik Ingelsson [Suède] ; Nancy L. Pedersen [Suède] ; Jonathan A. Prince [Suède] | Genome‐wide and gene‐based association implicates FRMD6 in alzheimer disease |
000328 (2011) |
Brian Jeynes [Canada] ; John Provias [Canada] | The case for blood–brain barrier dysfunction in the pathogenesis of Alzheimer's disease |
000474 (2011) |
Sheng Chen [Canada] ; Philip Seeman [Canada] ; Fang Liu [Canada] | Antipsychotic drug binding in the substantia nigra: An examination of high metoclopramide binding in the brains of normal, Alzheimer's disease, Huntington's disease, and Multiple Sclerosis patients, and its relation to tardive dyskinesia |
000497 (2010) |
Adrian W. Laxton [Canada] ; David F. Tang-Wai [Canada] ; Mary Pat Mcandrews [Canada] ; Dominik Zumsteg [Suisse] ; Richard Wennberg [Canada] ; Ron Keren [Canada] ; John Wherrett [Canada] ; Gary Naglie [Canada] ; Clement Hamani [Canada] ; Gwenn S. Smith [États-Unis] ; Andres M. Lozano [Canada] | A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease |
000546 (2010) |
Dylan G. Harwood [États-Unis] ; Ari Kalechstein [États-Unis] ; Warren W. Barker [États-Unis] ; Silvia Strauman [États-Unis] ; Peter St. George-Hyslop [Canada] ; Casandra Iglesias [États-Unis] ; David Loewenstein [États-Unis] ; Ranjan Duara [États-Unis] | The effect of alcohol and tobacco consumption, and apolipoprotein E genotype, on the age of onset in Alzheimer's disease |
000776 (2009) |
Jianjia Fan [Canada] ; James Donkin [Canada] ; Cheryl Wellington [Canada] | Greasing the wheels of Aβ clearance in Alzheimer's Disease: The role of lipids and apolipoprotein E |
000A67 (2007) |
S. Gauthier [Canada] ; A. Juby [Canada] ; B. Rehel [Canada] ; R. Schecter [Canada] | EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease |
000D57 (2004) |
Nathan Herrmann [Canada] ; Krista L. Lanctôt [Canada] ; Goran Eryavec [Canada] ; Lyla R. Khan [Canada] | Noradrenergic Activity is Associated with Response to Pindolol in Aggressive Alzheimer’s Disease Patients |
000E70 (2003) |
Mahyar Etminan [Canada] ; Sudeep Gill [Canada] ; Ali Samii [États-Unis] | Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies |
001168 (2000) |
Jeff A. Small [Canada] ; Susan Kemper [États-Unis] ; Kelly Lyons | Sentence Repetition and Processing Resources in Alzheimer's Disease |
001225 (2000) |
C. F. Lippa [États-Unis] ; J. M. Swearer [États-Unis] ; K. J. Kane [États-Unis] ; D. Nochlin [États-Unis] ; T. D. Bird [États-Unis] ; B. Ghetti [États-Unis] ; L. E. Nee [États-Unis] ; P. St. George-Hyslop [Canada] ; D. A. Pollen [États-Unis] ; D. A. Drachman [États-Unis] | Familial Alzheimer's disease: Site of mutation influences clinical phenotype |
001363 (1999) |
Pierre Chagnon [Canada] ; Mark Gee [Canada] ; Mario Filion [Canada] ; Yves Robitaille [Canada] ; Majid Belouchi [Canada] ; Denis Gauvreau [Canada] | Phylogenetic analysis of the mitochondrial genome indicates significant differences between patients with Alzheimer disease and controls in a French‐Canadian founder population |
001488 (1998) |
Edith G. Mcgeer [Canada] ; Patrick L. Mcgeer [Canada] | The importance of inflammatory mechanisms in alzheimer disease |
001495 (1998) |
Gloria S. Waters [Canada] ; Elizabeth Rochon [Canada] ; David Caplan [États-Unis] | Task Demands and Sentence Comprehension in Patients with Dementia of the Alzheimer's Type |
001562 (1998) |
R. B. Perl [États-Unis] ; C. Olanow Warren [États-Unis] ; Donald Calne [Canada] | Alzheimer's disease and parkinson's disease: Distinct entities or extremes of a spectrum of neurodegeneration? |
001670 (1997) |
Robert F. Lopez-Alberola [États-Unis, Canada] ; Warren W. Barker [États-Unis, Canada] ; Dylan G. Harwood [États-Unis, Canada] ; David A. Loewenstein [États-Unis, Canada] ; Peter H. St. George-Hyslop [États-Unis, Canada] ; Takehide Tsuda [États-Unis, Canada] ; Evgeny A. Rogaeva [États-Unis, Canada] ; Ranjan Duara [États-Unis, Canada] | Interfamilial and Intrafamilial Phenotypic Heterogeneity in Familial Alzheimer's Disease |
001883 (1996) |
J. J. Claus [Pays-Bas] ; E. Mohr [Canada] | Attentional deficits in Alzheimer's, Parkinson's, and Huntington's diseases |
001A20 (1995) |
Ronald A. Schipper [Canada] ; S. Cissé [Canada] ; E. G. Stopa [États-Unis] | Expression of heme oxygenase‐1 in the senescent and alzheimer‐diseased brain |